Postmenopausal Atrophic Vaginitis

Categories: Reproductive diseases

Aliases & Classifications for Postmenopausal Atrophic Vaginitis

MalaCards integrated aliases for Postmenopausal Atrophic Vaginitis:

Name: Postmenopausal Atrophic Vaginitis 12 15 72 33
Atrophic Vaginitis 12 75 17
Senile Vaginitis 12


External Ids:

Disease Ontology 12 DOID:11968
ICD9CM 35 627.3
SNOMED-CT 68 52441000
ICD10 33 N95.2
UMLS 72 C0156409

Summaries for Postmenopausal Atrophic Vaginitis

Disease Ontology : 12 A vaginitis that occurs in postmenopausal women and is characterized by vaginal atrophy secondary to estrogen deficiency.

MalaCards based summary : Postmenopausal Atrophic Vaginitis, also known as atrophic vaginitis, is related to vaginitis and osteoporosis. An important gene associated with Postmenopausal Atrophic Vaginitis is NHS (NHS Actin Remodeling Regulator), and among its related pathways/superpathways are Prolactin Signaling Pathway and TGF-beta Signaling Pathways. The drugs Apricot and Estrogens have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and cervix, and related phenotypes are behavior/neurological and adipose tissue

Wikipedia : 75 Atrophic vaginitis is inflammation of the vagina as a result of tissue thinning due to not enough... more...

Related Diseases for Postmenopausal Atrophic Vaginitis

Diseases related to Postmenopausal Atrophic Vaginitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 vaginitis 30.4 ESR2 ESR1 AR
2 osteoporosis 29.0 SHBG ESR2 ESR1 AR
3 47, xxy 10.3 SHBG AR
4 progesterone-receptor positive breast cancer 10.3 ESR2 ESR1
5 lipid-rich carcinoma 10.3 PRLR ESR1
6 androgen insensitivity, partial 10.3 SHBG AR
7 progesterone resistance 10.3 ESR2 ESR1
8 alopecia, androgenetic, 1 10.2 SHBG AR
9 oncocytic breast carcinoma 10.2 ESR1 AR
10 endometrial squamous cell carcinoma 10.2 ESR1 AR
11 dental fluorosis 10.2 ESR2 ESR1
12 endometriosis of ovary 10.2 ESR2 ESR1
13 apocrine adenocarcinoma 10.2 ESR1 AR
14 diffuse peritoneal leiomyomatosis 10.2 ESR1 AR
15 complete androgen insensitivity syndrome 10.2 SHBG AR
16 peritoneal benign neoplasm 10.2 ESR1 AR
17 breast adenoid cystic carcinoma 10.2 ESR1 AR
18 androgen insensitivity syndrome 10.2 SHBG AR
19 sebaceous gland disease 10.2 SHBG AR
20 androgenic alopecia 10.2 SHBG AR
21 transsexualism 10.2 ESR2 AR
22 testicular germ cell cancer 10.1 ESR2 AR
23 acute cystitis 10.1
24 lobular neoplasia 10.0 PRLR ESR2 ESR1
25 cervical polyp 10.0
26 vulvitis 10.0
27 vaginal discharge 10.0
28 prostatic hypertrophy 10.0 ESR1 AR
29 multiple personality disorder 10.0 OXT EHD1
30 estrogen excess 10.0 SHBG ESR2 ESR1
31 ovarian disease 9.9 SHBG ESR2 ESR1
32 gynecomastia 9.9 SHBG ESR1 AR
33 gonadal disease 9.9 SHBG ESR1 AR
34 male reproductive system disease 9.9 SHBG ESR2 AR
35 prostatic hyperplasia, benign 9.9 SHBG ESR2 AR
36 male reproductive organ cancer 9.9 SHBG ESR2 AR
37 breast cancer 9.9
38 pelvic organ prolapse 9.9
39 bone mineral density quantitative trait locus 8 9.9
40 bone mineral density quantitative trait locus 15 9.9
41 endometrial hyperplasia 9.9
42 squamous cell carcinoma 9.9
43 47,xyy 9.9
44 endometrial disease 9.9 OXT ESR1
45 fetishism 9.9 OXT KHDRBS3
46 transvestism 9.9 OXT KHDRBS3
47 gender identity disorder 9.8 ESR2 ESR1 AR
48 premenstrual tension 9.8 SHBG OXT
49 germ cell cancer 9.8 ESR2 ESR1 AR
50 estrogen-receptor negative breast cancer 9.8 ESR1 AR

Comorbidity relations with Postmenopausal Atrophic Vaginitis via Phenotypic Disease Network (PDN):

Acute Cystitis Anxiety
Deficiency Anemia Female Stress Incontinence
Hypertension, Essential Hypothyroidism

Graphical network of the top 20 diseases related to Postmenopausal Atrophic Vaginitis:

Diseases related to Postmenopausal Atrophic Vaginitis

Symptoms & Phenotypes for Postmenopausal Atrophic Vaginitis

MGI Mouse Phenotypes related to Postmenopausal Atrophic Vaginitis:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.76 AR ESR1 ESR2 FLNA KHDRBS3 OXT
2 adipose tissue MP:0005375 9.65 AR ESR1 ESR2 OXT PRLR
3 no phenotypic analysis MP:0003012 9.35 EHD1 ESR1 ESR2 KHDRBS3 NHS
4 reproductive system MP:0005389 9.28 AR EHD1 ESR1 ESR2 FLNA KHDRBS3

Drugs & Therapeutics for Postmenopausal Atrophic Vaginitis

Drugs for Postmenopausal Atrophic Vaginitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Apricot Approved Phase 4
2 Estrogens Phase 4
3 Hormones Phase 4
4 Hormone Antagonists Phase 4
5 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
6 Estrogens, Conjugated (USP) Phase 4
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
Polyestradiol phosphate Approved Phase 3 28014-46-2
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
11 Pycnogenols Phase 3
12 Antineoplastic Agents, Hormonal Phase 3
13 Contraceptives, Oral Phase 3
14 Central Nervous System Stimulants Phase 3
15 Appetite Stimulants Phase 3
Megestrol Phase 3 3562-63-8 3080587 19090
17 Immunologic Factors Phase 3
18 Adjuvants, Immunologic Phase 3
19 Aromatase Inhibitors Phase 3
20 DHEA (Dehydroepiandrosterone) Phase 3
21 Steroid Synthesis Inhibitors Phase 3
22 Estrogen Receptor Antagonists Phase 3
23 Estrogen Antagonists Phase 3
24 Contraceptive Agents Phase 3
25 Estradiol 17 beta-cypionate Phase 3
26 Estradiol 3-benzoate Phase 3
Echinacea Approved, Experimental Phase 1, Phase 2
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
Loperamide Approved Phase 2 53179-11-6 3955
Calcium polycarbophil Approved Phase 2 126040-58-2
Caffeine Approved Phase 2 58-08-2 2519
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
Methyltestosterone Approved Phase 1, Phase 2 58-18-4 6010
Testosterone enanthate Approved Phase 1, Phase 2 315-37-7 9416
Testosterone Approved, Experimental, Investigational Phase 1, Phase 2 481-30-1, 58-22-0 6013 10204
Testosterone undecanoate Approved, Investigational Phase 1, Phase 2 5949-44-0
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
38 Omega 3 Fatty Acid Phase 2
39 Gotu Kola Phase 1, Phase 2
40 Oxytocics Phase 2
41 Calcium, Dietary Phase 2
42 Psyllium Phase 2
43 Gastrointestinal Agents Phase 2
44 Cathartics Phase 2
45 Laxatives Phase 2
46 Antidiarrheals Phase 2
47 Progestins Phase 2
48 Androgens Phase 1, Phase 2
49 Anabolic Agents Phase 1, Phase 2
50 Testosterone 17 beta-cypionate Phase 1, Phase 2

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 The Effects of Vaginal Estrogen and a Nonhormonal Alternative on the Vaginal and Urinary Microbiome in Women With Genitourinary Syndrome of Menopause: A Randomized Controlled Trial Unknown status NCT02869165 Phase 4 Premarin vaginal cream;Apricot kernel oil
2 Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis Completed NCT02014428 Phase 4 Placebo
3 Randomized, Blinded Trial Comparing Vaginal Estrogens on Pelvic Organ Prolapse Patients Completed NCT03032848 Phase 4 Conjugated Estrogen;Promestriene;Estriol;Vaginal Moisturizer - Cream
4 IMPLORE Study: Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy Not yet recruiting NCT03996603 Phase 4 Conjugated Estrogens Cream
5 A 12 Month Double-blind, Randomized, Parallel-group, Placebo-controlled, Multi-center Trial to Investigate the Efficacy and Safety of Vagifem Low Dose (10 mcg 17beta-estradiol Vaginal Tablet) for the Treatment of Postmenopausal Atrophic Vaginitis Symptoms Completed NCT00108849 Phase 3 estradiol, 10 mcg
6 Efficacy and Safety of 2 Low-Dose Regimens of Conjugated Estrogen Cream Administered Vaginally in Postmenopausal Women With Atrophic Vaginitis Completed NCT00137371 Phase 3 PVC (daily for 21 days, 7 days off);PVC (twice weekly)
7 Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis Completed NCT00464971 Phase 3 estradiol, 25 mcg
8 Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Cream, 0.01% to Estrace® Estradiol Vaginal Cream 0.01% in Atrophic Vaginitis Completed NCT03294538 Phase 3 Estrace® Cream;Generic Estradiol Cream;Vehicle Cream
9 Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Alvogen Pine Brook LLC.) to Estrace® Cream (0.01%; Warner Chilcott) in Postmenopausal Females With Atrophic Vaginitis Completed NCT02995694 Phase 3 Estradiol;Placebos;Reference
10 A 12 Month, Open-label, Multi-center Trial to Investigate the Endometrial Safety of Vagifem Low Dose (10ug 17beta-estradiol Vaginal Tablet) in Postmenopausal Women With Atrophic Vaginitis Symptoms Completed NCT00431132 Phase 3 estradiol, 10 mcg
11 Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Mylan) to Estrace® Cream (0.01%; Warner Chilcott) in Postmenopausal Females With Atrophic Vaginitis Completed NCT02195986 Phase 3 Estradiol Vaginal Cream, 0.01%;Estrace® 0.01% cream;Placebo Vaginal Cream
12 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Comparing the Efficacy and Safety of 17-Beta Estradiol 10 Micrograms and 25 Micrograms (Vagifem) Doses in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis Completed NCT00465192 Phase 3 estradiol, 10 mcg;estradiol, 25 mcg;placebo
13 An Investigator-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, USP 10 mcg and Vagifem® (Estradiol Vaginal Tablets) 10 mcg and Compare Both Active Treatments to a Placebo Control in Female Subjects With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Associated With Menopause Completed NCT01779947 Phase 3 Estradiol Vaginal Tablets 10 mcg;placebo
14 Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause Completed NCT02013544 Phase 3 Placebo;Prasterone (DHEA)
15 DHEA Against Vaginal Atrophy - Safety Study of 12 Months Completed NCT01256671 Phase 3 DHEA
16 Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy Completed NCT01358760 Phase 3 Placebo;DHEA;DHEA
17 DHEA Against Vaginal Atrophy (Placebo-controlled, Double-blind and Randomized Phase III Study of 3-month Intravaginal DHEA) Completed NCT01256684 Phase 3 Placebo;DHEA;DHEA
18 Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study) Completed NCT01846442 Phase 3 Placebo;DHEA (0.25%);DHEA (0.5%);DHEA (1.0%)
19 The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse: A Randomized Control Trial Completed NCT00803335 Phase 3 Vaginal conjugated estrogen cream 0.5gm;Vaginal conjugated estrogen cream 1.0gm
20 A Phase III Trial of Placebo Versus Megestrol Acetate 20 MG/Day Versus Megestrol Acetate 40 MG/Day as Treatment for Symptoms of Ovarian Failure in Women Treated for Breast Cancer: SWOG Study S9626 Completed NCT00005975 Phase 3 Megestrol Acetate 20mg/day;Megestrol Acetate 40 mg/day;Megestrol Acetate Placebo 20 mg/day;Megestrol Acetate Placebo 40 mg/day
21 Effect of Intravaginal Prasterone (DHEA) on Moderate to Severe Symptoms of Vulvovaginal Atrophy Due to Menopause, in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer - (Placebo-Controlled, Double Blind and Randomized Phase III Study) Not yet recruiting NCT03740945 Phase 3 Placebo;Prasterone (DHEA)
22 A Randomized Controlled Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis Terminated NCT00816556 Phase 3 Estriol;Estradiol valerate;Vanicream Lite
24 A Randomized Trial to Explore the Effect of Oral Omega 3 Fatty Acids on Atrophic Vaginitis in Postmenopausal Breast Cancer Survivors Completed NCT02150525 Phase 2
25 Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of Atrophic Vaginitis or Desquamative Inflammatory Vaginitis Completed NCT02313545 Phase 1, Phase 2 IZN-6NVS Cream
26 A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled, Multiple-Dose Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy Completed NCT02497547 Phase 2 Oxytocin;Placebo
27 Microbiological Impact of a Cream and the Feeling of Softness and Freshness in the Intimate Area of Women Completed NCT02162160 Phase 2 Placebo
28 H- 30956 REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy Recruiting NCT01984138 Phase 2 ESTRING;Replens
29 Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy - a Double Blind Randomized Control Trial Recruiting NCT02460302 Phase 2 Vaginal progesterone;Placebo
30 Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer. Suspended NCT01122342 Phase 1, Phase 2 Testosterone propionate
31 The Treatment Effect of Chinese Herbal Compound Ointment on Atrophic Vaginitis Unknown status NCT02733731 Phase 1 Chinese Herbal Compound Ointment;Estriol
32 A Multiple-Dose, Comparative Bioavailability Study of Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Postmenopausal Women With Atrophic Vaginitis. Completed NCT00167921 Phase 1 Premarin® Vaginal Cream;Premarin® oral tablets
33 A Clinical Study of Pharmacokinetics, Efficacy and Safety of Vaginal Application of Lyophilised Lactobacilli and 0.03 mg Estriol (Gynoflor®) on Atrophic Vaginitis in Postmenopausal Breast Cancer Patients Treated With Aromatase Inhibitors Completed NCT01370551 Phase 1 Gynoflor
34 A Pharmacokinetic Randomized Study With a Parallel Group Design to Assess the Extent of Systemic Absorption of Estradiol During Treatment With a 10 µg or 25 µg Estradiol Vaginal Tablet Administered Once Daily for 2 Weeks Followed by 10 Weeks of Twice-Weekly Maintenance Therapy in Postmenopausal Women With Atrophic Vaginitis Completed NCT01486979 Phase 1 estradiol, 10 mcg;estradiol, 25 mcg
35 An Open Randomized Two-Way Cross-Over Comparative Bioavailability Study to Compare the Extent of Systemic Absorption of Estradiol After a Single Dose Treatment With Two 25 mcg Estradiol Vaginal Tablet Formulations Administered in Postmenopausal Women With Vaginal Atrophy Completed NCT01085877 Phase 1 estradiol, 25 mcg;estradiol, 25 mcg
36 Effect of PRP Injection in Releiving of Symptoms of Senile Vaginitis Recruiting NCT03898401 Phase 1
37 Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency Completed NCT01507454 estradiol, 25 mcg
38 A Randomized Clinical Trial Comparing Vaginal Laser Therapy to Vaginal Estrogen Therapy in Women With Genitourinary Syndrome of Menopause Completed NCT02691936 Estrogens, Conjugated (USP)
39 VR101: A Pilot Study to Evaluate the Preliminary Feasibility and Safety of a Lubricating Intravaginal Ring to Relieve the Symptoms of Vaginal Dryness Completed NCT02029053 Early Phase 1
40 Hyaluronate for the Treatment and Prevention of Recurrent Urinary Tract Infection in Women Suffering Atrophic Vaginitis Recruiting NCT03981458
41 A Review on the Outcome of Patient Managed in One Stop Postmenopausal Bleeding Clinic in New Territories East Cluster, NTEC Recruiting NCT03382145
42 Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen Active, not recruiting NCT00984399 Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
43 LASER and Radiofrequency as Alternative Treatments for Genitourinary Syndrome of Menopause Not yet recruiting NCT04045379 Estriol
44 Laser Treatment of Genito-urinary Syndrome in Women With Breast and Endometrial Cancer and Menopausal Women Not yet recruiting NCT03238053

Search NIH Clinical Center for Postmenopausal Atrophic Vaginitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Conjugated estrogens

Genetic Tests for Postmenopausal Atrophic Vaginitis

Anatomical Context for Postmenopausal Atrophic Vaginitis

MalaCards organs/tissues related to Postmenopausal Atrophic Vaginitis:

Breast, Testes, Cervix

Publications for Postmenopausal Atrophic Vaginitis

Articles related to Postmenopausal Atrophic Vaginitis:

(show top 50) (show all 191)
# Title Authors PMID Year
Prevalence and Risk Factors of Stress Urinary Incontinence Among Perimenopausal Women and Its Influence on Daily Life in Women with Sexual Desire Problem. 38
31346999 2019
Plasma cell vulvitis presenting as postmenopausal atrophic vaginitis - a case report. 38
31018733 2019
[Experience of application of hormonal and probiotic therapy in the complex treatment of women in peri- and postmenopausal with chronic recurrent bacterial cystitis in the background of vulvovaginal atrophy]. 38
31356015 2019
Comparison of the effect of hyaluronic acid and estrogen on atrophic vaginitis in menopausal women: A systematic review. 38
30798700 2019
Associations of birth characteristics with perimenopausal disorders: a prospective cohort study. 38
30296955 2019
Device-based treatment for vaginal wellness. 38
30475926 2018
Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. 38
30358729 2018
17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. 38
30358715 2018
2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. 38
30049258 2018
Diagnosis and Treatment of Genitourinary Syndrome of Menopause. 38
30170002 2018
Application of conjugated estrogen cream in the treatment of postmenopausal atrophic vaginitis. 38
30463825 2018
Nephrogenic Adenoma in the Setting of Refractory Labial Agglutination in an Elderly Woman. 38
29489552 2018
ACOG Committee Opinion No. 740 Summary: Gynecologic Care for Adolescents and Young Women With Eating Disorders. 38
29794675 2018
ACOG Committee Opinion No. 740: Gynecologic Care for Adolescents and Young Women With Eating Disorders. 38
29794682 2018
Histologic and Clinical Changes in Vulvovaginal Tissue After Treatment With a Transcutaneous Temperature-Controlled Radiofrequency Device. 38
29701623 2018
Tuberculosis of the cervix: An uncommon cause of vaginal discharge in a post-menopausal woman. 38
31044761 2018
Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. 38
29347848 2018
Therapeutic Approaches to Atrophic Vaginitis in Postmenopausal Women: A Systematic Review with a Network Meta-analysis of Randomized Controlled Trials. 38
29765921 2018
[Acquired clitoral phimosis causing a periclitoral pseudocyst]. 38
29536840 2018
Genital diseases in the mature woman. 38
29566925 2018
Vaginitis: Diagnosis and Treatment. 38
29671516 2018
[La ménopause et le traitement hormonal de la ménopause : une actualisation]. 38
30320986 2018
Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. 38
29202940 2017
Chitosan Ascorbate Nanoparticles for the Vaginal Delivery of Antibiotic Drugs in Atrophic Vaginitis. 38
29048359 2017
A Dermatologist's Approach to Genitourinary Syndrome of Menopause. 38
28453946 2017
Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy. 38
28805983 2017
False-Negative Interpretation of Adenocarcinoma In Situ in the College of American Pathologists Gynecologic PAP Education Program. 38
28301226 2017
Study of pruritus vulvae in geriatric age group in tertiary hospital. 38
28442799 2017
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. 38
27472999 2016
Erratum: Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. 38
27897166 2016
Prevalence and risk factors of urinary incontinence among perimenopausal women in Wuhan. 38
27752911 2016
ThermiVa: The Revolutionary Technology for Vulvovaginal Rejuvenation and Noninvasive Management of Female SUI. 38
27382227 2016
Genitourinary syndrome of menopause: A new name for an old condition. 38
27327425 2016
Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. 38
27178335 2016
Common Questions About Recurrent Urinary Tract Infections in Women. 38
27035041 2016
Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. 38
27103314 2016
Spontaneous Reproductive Tract Lesions in Aged Captive Chimpanzees. 38
26823448 2016
A comparative study of vaginal estrogen cream and sustained-release estradiol vaginal tablet (Vagifem) in the treatment of atrophic vaginitis in Isfahan, Iran in 2010-2012. 38
26958050 2015
Transcutaneous Temperature Controlled Radiofrequency for Atrophic Vaginitis and Dyspareunia. 38
27679110 2015
Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. 38
26223323 2015
Does a diagnosis of atrophic vaginitis on Papanicolaou test signify the presence of inflammation? 38
25535962 2015
The Recent Review of the Genitourinary Syndrome of Menopause. 38
26357643 2015
Female sexual dysfunction. 38
25841603 2015
Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. 38
25427450 2015
Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. 38
25815692 2015
Using Wood's Light as a Diagnostic Tool for Vaginal Atrophy. 38
25738039 2015
Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. 38
25201455 2015
Management of persistent vaginitis. 38
25415165 2014
Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. 38
25087944 2014
Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. 38
24718774 2014

Variations for Postmenopausal Atrophic Vaginitis

Expression for Postmenopausal Atrophic Vaginitis

Search GEO for disease gene expression data for Postmenopausal Atrophic Vaginitis.

Pathways for Postmenopausal Atrophic Vaginitis

GO Terms for Postmenopausal Atrophic Vaginitis

Biological processes related to Postmenopausal Atrophic Vaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription initiation from RNA polymerase II promoter GO:0006367 9.43 ESR2 ESR1 AR
2 intracellular receptor signaling pathway GO:0030522 9.37 ESR1 AR
3 transcription, DNA-templated GO:0006351 9.32 ESR1 AR
4 intracellular estrogen receptor signaling pathway GO:0030520 9.16 ESR2 ESR1
5 mammary gland alveolus development GO:0060749 8.96 ESR1 AR
6 cytoplasmic sequestering of protein GO:0051220 8.62 GET4 FLNA

Molecular functions related to Postmenopausal Atrophic Vaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 9.54 ESR2 ESR1 AR
2 estrogen receptor activity GO:0030284 9.4 ESR2 ESR1
3 lipid binding GO:0008289 9.35 TTPA SHBG ESR2 ESR1 AR
4 nuclear receptor activity GO:0004879 9.33 ESR2 ESR1 AR
5 estrogen response element binding GO:0034056 9.32 ESR2 ESR1
6 androgen binding GO:0005497 9.26 SHBG AR
7 steroid binding GO:0005496 8.92 SHBG ESR2 ESR1 AR

Sources for Postmenopausal Atrophic Vaginitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....